Clinical Trials · NCT07537088
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
- Phase
- Phase 4
- Recruitment status
- Not Yet Recruiting
- Sponsor
- First Affiliated Hospital of Wannan Medical College
- Enrollment
- 468
- Start date
- May 2026
- Locations
- See registry
- Primary endpoint
- Urine Albumin-to-Creatinine Ratio（UACR）